FORBES-TATE

Lobbying for ALEXION PHARMACEUTICALS, INC. · Biopharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $50,000.00 income · posted Apr 17, 2026

Lobbying activity 2

Health Issues

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.

Medicare/Medicaid

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.